Human papillomavirus vaccine update

Alisa Ames, Patti Gravitt

Research output: Contribution to journalArticle

Abstract

With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papilomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18 - the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.

Original languageEnglish (US)
Pages (from-to)151-158
Number of pages8
JournalCurrent Infectious Disease Reports
Volume9
Issue number2
DOIs
StatePublished - Mar 2007

Fingerprint

Papillomavirus Vaccines
Vaccines
Vaccination
Public Policy
Health Policy
Administrative Personnel
Uterine Cervical Neoplasms
Randomized Controlled Trials
Public Health
Parents
Infection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Human papillomavirus vaccine update. / Ames, Alisa; Gravitt, Patti.

In: Current Infectious Disease Reports, Vol. 9, No. 2, 03.2007, p. 151-158.

Research output: Contribution to journalArticle

Ames, Alisa ; Gravitt, Patti. / Human papillomavirus vaccine update. In: Current Infectious Disease Reports. 2007 ; Vol. 9, No. 2. pp. 151-158.
@article{fcc71578afba464cbe4ba1b525641e55,
title = "Human papillomavirus vaccine update",
abstract = "With the approval of Gardasil{\circledR} (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix{\circledR} (GlaxoSmithKline, London, UK), two prophylactic human papilomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18 - the types responsible for 70{\%} of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.",
author = "Alisa Ames and Patti Gravitt",
year = "2007",
month = "3",
doi = "10.1007/s11908-007-0011-6",
language = "English (US)",
volume = "9",
pages = "151--158",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Human papillomavirus vaccine update

AU - Ames, Alisa

AU - Gravitt, Patti

PY - 2007/3

Y1 - 2007/3

N2 - With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papilomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18 - the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.

AB - With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papilomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18 - the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.

UR - http://www.scopus.com/inward/record.url?scp=33947273719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947273719&partnerID=8YFLogxK

U2 - 10.1007/s11908-007-0011-6

DO - 10.1007/s11908-007-0011-6

M3 - Article

C2 - 17324353

AN - SCOPUS:33947273719

VL - 9

SP - 151

EP - 158

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 2

ER -